^
Association details:
| Biomarker: | CD123 positive |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | BYON4413 (CD123-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2795 Potent in Vitro and In Vivo Efficacy of BYON4413, a Duba-Based Antibody-Drug Conjugate Targeting CD123 in Acute Myeloid Leukemia
Published date:
11/02/2023
Excerpt:
In vitro studies with AML cell lines demonstrate that BYON4413 is highly effective in eradicating CD123-positive cells while having little impact on CD123-negative cells.
